By Ilan Zipkin
Staff writer
NIH Director Harold Varmus last week cited the need to ensure that biotech and pharmaceutical companies do not obtain control over basic technologies as one factor behind the government's decision that NIH will fund research on human pluripotent stem cells, including embryonic stem (ES) cells and embryonic germ (EG) cells